Chronic Kidney Disease: Why eGFR and Urine Albumin Must Be Read Together

Chronic kidney disease testing uses two complementary measurements: an eGFR test, usually calculated first from serum creatinine, and a urine albumin test, most often reported as the urine albumin-to-creatinine ratio (UACR). The eGFR test estimates how well the kidneys filter blood, while the urine albumin test helps identify kidney damage by detecting albumin leakage. Because either result can become abnormal before the other, both should be interpreted together, confirmed over time, and evaluated in the appropriate clinical context. For adults at risk for chronic kidney disease (CKD), KDIGO recommends estimating the GFR category with a combined creatinine–cystatin C equation when cystatin C is available. The Estimated Glomerular Filtration Rate (eGFR) with Creatinine and Cystatin C test may improve precision, but it does not replace UACR testing or diagnose CKD by itself.¹

This article is educational. Laboratory results do not replace a medical history, examination, imaging, medication review, or care from a qualified healthcare professional.

In This Article

One blood result cannot show the full kidney picture. Pairing estimated glomerular filtration rate with urine albumin helps reveal both filtration and damage.

• Key takeaways
• What chronic kidney disease means
• Why eGFR and urine albumin answer different questions
• How GFR and albuminuria categories work
• Who may benefit from testing
• Why combining creatinine and cystatin C can improve eGFR accuracy
• A practical testing approach
• How to prepare and when to repeat testing
• How to understand results and trends
• When prompt care is needed
• Frequently asked questions

Part of the Ulta Lab Tests Kidney Health Knowledge Center

This focused guide expands on the broader kidney health lab testing overview and the detailed guide to CKD stages, causes, symptoms, and tests. For broader guidance on specimens, panels, and test selection, see the Complete Guide to Lab Tests and Blood Work. Readers whose creatinine result may be misleading can also review the focused article on cystatin C and eGFR accuracy.

Key Takeaways

• eGFR estimates filtration; urine albumin helps identify kidney damage. Neither replaces the other.
• A person can have persistent albuminuria with an eGFR above 60, or a low eGFR with little albumin in the urine.
• CKD generally requires a kidney abnormality that persists for at least three months, unless other evidence already establishes chronicity.
• Kidney risk is classified by cause, GFR category, and albuminuria category, often abbreviated CGA.
• A first-morning urine sample is preferred for confirming an elevated random urine albumin result.
• Creatinine-based eGFR is the usual initial filtration estimate. In adults at risk for CKD, KDIGO recommends using the combined creatinine-cystatin C estimate to assign the GFR category when cystatin C is available; the combined estimate is especially useful when creatinine may be inaccurate or a clinical decision depends on GFR.¹
• Sudden kidney changes, very low urine output, severe swelling, breathing difficulty, confusion, or symptoms of a dangerous electrolyte imbalance require prompt medical evaluation.

Key Kidney Testing Facts

Test or group	Specimen	Fasting or timing	Primary purpose	Use status	Major limitation
Creatinine Test with eGFR	Blood	Fasting is not always required; collection conditions should be comparable for trends	Estimates kidney filtration	Common or first-line	Creatinine is influenced by muscle mass, diet, supplements, and some medications
Albumin Random Urine Test with Creatinine	Spot urine	First-morning midstream sample preferred for confirmation	Measures albumin leakage relative to urine concentration	Common or first-line	Exercise, infection, bleeding, and short-term illness can raise the result
Urinalysis Complete Test	Urine	Follow collection instructions; avoid contamination	Looks for blood, protein, glucose, cells, casts, and infection clues	Common or first-line	A dipstick may miss lower levels of albumin and does not replace quantitative UACR
Cystatin C Test with eGFR	Blood	Usually no fasting requirement unless combined with other tests	Adds another filtration marker when creatinine may be less reliable	Risk-based or targeted	Cystatin C also has non-GFR influences and does not replace clinical interpretation
Estimated Glomerular Filtration Rate (eGFR) with Creatinine and Cystatin C	Blood	Follow the instructions for the complete order	Uses both filtration markers to improve eGFR accuracy	Risk-based or targeted; guideline-preferred for GFR categorization in adults at risk for CKD when cystatin C is available	Still an estimate; it does not identify kidney damage, cause, or chronicity
Basic Metabolic Panel Test or Comprehensive Metabolic Panel Test - CMP	Blood	Fasting depends on the ordered panel and clinical question	Provides creatinine, glucose, and electrolyte or acid-base context	Common or first-line	Does not measure urine albumin and cannot classify CKD risk by itself
Complete Blood Count with Differential and Platelets	Blood	No fasting by itself	Assesses anemia and other blood-cell patterns	Risk-based or targeted	Low hemoglobin has many causes and is not specific to CKD

What Is Chronic Kidney Disease?

Chronic kidney disease is an abnormality of kidney structure or function that has implications for health and persists for at least three months. The definition does not depend on one creatinine number or an eGFR label alone. A persistent eGFR below 60 mL/min/1.73 m², persistent albuminuria, blood or abnormal sediment in the urine, structural changes, or certain inherited kidney disorders can establish the pattern when evaluated in context.¹

The kidneys filter waste and extra water, regulate electrolytes and acid-base balance, help control blood pressure, support red-blood-cell production, and participate in mineral and bone metabolism. CKD can therefore affect cardiovascular health, fluid balance, blood counts, medication handling, and bone health long before a person associates symptoms with the kidneys.

Early CKD is often silent. Fatigue, swelling, foamy urine, changes in urination, nausea, itching, cramps, or reduced exercise tolerance may occur, but these symptoms are not specific. Objective blood and urine testing can identify patterns that symptoms alone cannot, while imaging, examination, and sometimes specialist evaluation are needed to determine cause and severity.

Why eGFR and Urine Albumin Must Be Read Together

KDIGO recommends testing people at risk for CKD with both urine albumin measurement and an assessment of GFR.¹ NIDDK likewise describes GFR and urine albumin as the two principal tests used to detect and monitor kidney disease.² Their roles are different:

Question	eGFR	Urine albumin-to-creatinine ratio	Why both matter
What does it reflect?	Estimated filtration of blood	Albumin leakage through the kidney filters	Function and damage are related but not identical
Can it be abnormal first?	Yes; filtration can fall with little albuminuria	Yes; albumin can rise while eGFR remains above 60	Testing only one can miss an important pattern
How is it commonly obtained?	Calculated from a serum creatinine test; cystatin C may be added	Measured with an UACR test on a spot urine sample	The blood and urine samples answer separate questions
What can distort it?	Muscle mass, recent meat intake, creatine use, illness, medication effects, and assay variation	Exercise, urinary infection, fever, bleeding, hydration, and collection conditions	Unexpected results often require repeat testing under comparable conditions
What does it not establish alone?	Cause, chronicity, structural disease, or kidney damage with preserved filtration	Filtration level, cause, or whether one elevated result is persistent	Clinical history, trends, urinalysis, and sometimes imaging are still necessary

Four Patterns That Explain the Difference

1. eGFR above 60 with UACR below 30: CKD is not established by these two measurements alone. Other persistent markers of kidney damage could still matter.
2. eGFR above 60 with UACR at or above 30: Persistent albuminuria can indicate kidney damage even when filtration appears preserved.
3. eGFR below 60 with UACR below 30: Reduced filtration may reflect CKD, age-related change, vascular disease, prior injury, medication effects, or another cause. Persistence and context are essential.
4. eGFR below 60 with elevated UACR: Both filtration loss and albumin leakage are present; higher albuminuria generally indicates greater kidney and cardiovascular risk within the same GFR category.

How GFR and Albuminuria Categories Work

KDIGO classifies CKD by cause, GFR category, and albuminuria category, abbreviated CGA. The two laboratory axes are shown below. They are classification categories, not standalone diagnoses or individualized treatment targets.¹

GFR Categories

Category	eGFR (mL/min/1.73 m2)	Description
G1	90 or higher	Normal or high
G2	60-89	Mildly decreased
G3a	45-59	Mildly to moderately decreased
G3b	30-44	Moderately to severely decreased
G4	15-29	Severely decreased
G5	Below 15	Kidney failure category

G1 or G2 does not establish CKD without another persistent marker of kidney damage. An eGFR below 60 can support CKD when it persists for at least three months or when other evidence establishes chronicity.

Albuminuria Categories

Category	UACR (mg/g)	Description
A1	Below 30	Normal to mildly increased
A2	30-300	Moderately increased
A3	Above 300	Severely increased

A result at or above 30 mg/g on a random sample should generally be confirmed with a subsequent first-morning midstream sample. A single elevated result can be temporary; a persistent result carries different meaning.¹

Why the Combination Changes Risk

Two people with the same eGFR may have different risks if their urine albumin results differ. A G3a-A1 pattern generally carries less kidney-progression risk than G3a-A3. Conversely, G2-A3 can reflect meaningful kidney damage despite an eGFR above 60. The cause of the kidney pattern further changes risk and management, which is why CKD should not be reduced to a single stage number.

Who May Benefit from Chronic Kidney Disease Testing?

Kidney testing is especially relevant for people with diabetes, high blood pressure, cardiovascular disease, heart failure, obesity, a family history of kidney failure, prior acute kidney injury, recurrent stones or urinary obstruction, autoimmune disease, or previous abnormal kidney or urine results. The benefit of population-wide screening without risk factors is less clear; testing should answer a meaningful health question.³

The American Diabetes Association's 2026 guidance recommends annual spot UACR and eGFR screening for everyone with type 2 diabetes and for people who have had type 1 diabetes for five years or longer.⁴

Situation	What it may raise	Laboratory information that may help	Other evaluation that may be needed
Diabetes or persistently elevated glucose	Diabetic kidney disease risk	Creatinine Test with eGFR, UACR test, and A1c Test	Blood-pressure review, medication review, eye and cardiovascular assessment
High blood pressure, cardiovascular disease, or heart failure	Vascular kidney damage or reduced kidney perfusion	Creatinine Test with eGFR, UACR test, and electrolyte monitoring	Blood-pressure measurements, medication assessment, and cardiac evaluation when indicated
Foamy urine, swelling, or unexplained low blood albumin	Protein loss, fluid retention, liver disease, inflammation, or another cause	UACR test, complete urinalysis, and serum albumin test	Examination, medication review, and sometimes imaging or nephrology evaluation
Blood or dark urine, systemic inflammation, rash, or joint symptoms	Urinary bleeding, infection, stones, or glomerular inflammation	Urinalysis Complete Test, kidney filtration, and quantitative urine protein assessment	Prompt clinical evaluation; imaging, specialist-selected serology, or biopsy may be needed
Low muscle mass, amputation, extreme muscularity, or intensive training	A creatinine-derived eGFR that may not reflect true filtration accurately	Estimated Glomerular Filtration Rate (eGFR) with Creatinine and Cystatin C	Clinical assessment of body composition, illness, diet, and medication factors
Fatigue, weakness, cramps, itching, or reduced exercise tolerance with known CKD	Anemia, acid-base disturbance, mineral imbalance, medication effect, or disease progression	CBC, potassium test, carbon dioxide test, and risk-based mineral testing	Medical evaluation; urgent assessment if symptoms are severe or rapidly worsening

eGFR with Creatinine and Cystatin C: Why Combining Both Markers Can Be an Advantage

Estimated glomerular filtration rate (eGFR) estimates how efficiently the kidneys filter blood. Most routine eGFR results are calculated from serum creatinine. Although creatinine-based eGFR is an appropriate first-line measurement for many people, creatinine can be influenced by factors unrelated to kidney filtration, including muscle mass, frailty, amputation, recent meat intake, creatine supplements, intensive exercise, and certain medications.

The Specific Combined Test

The Estimated Glomerular Filtration Rate (eGFR) with Creatinine and Cystatin C measures both serum creatinine and cystatin C and uses them together to calculate a combined filtration estimate, abbreviated eGFRcr-cys.

Cystatin C is another blood marker filtered by the kidneys. It is generally less affected by muscle mass than creatinine. The race-free 2021 CKD-EPI combined equation uses age, sex, creatinine, and cystatin C. Using both markers generally produces a more accurate eGFR than using creatinine alone, particularly when the result is close to a value that could influence a clinical decision.⁷

Use status: Risk-based or targeted in this patient-facing testing framework. The combined test is not required for every routine kidney evaluation, but it may provide useful additional precision when creatinine alone may not accurately reflect filtration or when the result could affect staging, medication dosing, transplant evaluation, or another clinical decision.

How Current Kidney Guidance Positions the Combined Estimate

Creatinine-based eGFR is the usual initial GFR assessment. For adults at risk for CKD, KDIGO recommends estimating the GFR category with combined creatinine-cystatin C eGFR when cystatin C is available. KDIGO also recommends the combined estimate when creatinine-based eGFR may be less accurate and GFR affects clinical decision-making. When even greater accuracy is required—or the combined estimate may also be unreliable—measured GFR may be appropriate.¹

eGFR approach	Markers used	Potential advantage	Important limitation
Creatinine-based eGFR (eGFRcr)	Creatinine, age, and sex	Widely available and appropriate as a first-line filtration estimate	Muscle mass, diet, supplements, medications, and creatinine-assay factors can affect the result
Cystatin C-based eGFR (eGFRcys)	Cystatin C, age, and sex	Generally less dependent on muscle mass	Corticosteroids, thyroid dysfunction, adiposity, inflammation, smoking, and acute illness can affect cystatin C
Combined eGFR (eGFRcr-cys)	Creatinine, cystatin C, age, and sex	Balances two markers with different non-GFR influences and generally improves accuracy	Remains an estimate and may still be inaccurate when one or both markers are substantially affected by non-kidney factors

Why Combining Both Markers Can Be an Advantage

• It reduces reliance on one imperfect marker. Creatinine and cystatin C are affected by different non-kidney factors. Combining them can offset some of the error associated with using either marker alone.⁸
• It improves accuracy on average. The combined eGFRcr-cys equation generally agrees more closely with measured GFR than an equation based only on creatinine or cystatin C.¹
• It can reduce uncertainty near a decision threshold. Additional precision may matter when a small difference could change a CKD GFR category, medication-dosing decision, transplant evaluation, or other clinical plan.
• It may reduce GFR misclassification. A more accurate estimate can help a healthcare professional determine whether kidney filtration probably falls above or below an important cutoff.
• It provides context for an unexpected creatinine result. Measuring both markers can be helpful when creatinine-based eGFR appears inconsistent with a person's body composition, medical history, previous results, or overall clinical picture.
• It helps evaluate discordant results. Differences between creatinine-based and cystatin C-based estimates can provide clues about non-GFR factors affecting either marker and help guide further evaluation. When the two estimates disagree, KDIGO reports that the combined estimate is generally more accurate than either estimate alone.¹

When the Combined Test May Be Especially Useful

A healthcare professional may consider the Estimated Glomerular Filtration Rate (eGFR) with Creatinine and Cystatin C when:

• Muscle mass is unusually low or high because of frailty, amputation, paralysis, muscle-wasting disease, bodybuilding, or intensive strength training.
• Diet, creatine supplementation, or a medication may be affecting serum creatinine.
• A creatinine-based eGFR result is unexpected or does not fit other clinical findings.
• The result is close to a CKD classification or clinical decision threshold.
• A more accurate filtration estimate could influence medication dosing, transplant evaluation, or another important decision.
• The creatinine-based and cystatin C-based estimates need to be compared because kidney-function classification remains uncertain.

Important Limitations

The combined result is still an estimate, not a direct measurement of GFR. If either marker has a strong non-GFR influence, the combined equation may not be the most reliable option. A healthcare professional may place greater weight on the less-affected marker or use measured GFR when unusually high accuracy is required.

eGFR equations can also be less reliable during acute kidney injury, rapidly changing kidney function, critical illness, pregnancy, or other situations in which filtration markers are unstable. Results should be interpreted with medical history, medications, current health status, previous measurements, and trends.

Most laboratory eGFR values are indexed to a standard body-surface area of 1.73 m². For medication dosing in a person whose body size is substantially different from average, a healthcare professional may need a non-indexed GFR calculation. Drugs with a narrow therapeutic index or high toxicity may require a combined estimate or measured GFR when accuracy is especially important. Do not start, stop, or change a medication dose based solely on an online eGFR result.⁹

Most importantly, eGFRcr-cys evaluates kidney filtration; it does not measure kidney damage. It does not reveal urine albumin leakage, determine the cause of kidney disease, or establish that an abnormality has persisted long enough to meet the definition of chronic kidney disease. A complete kidney assessment may also require an Albumin Random Urine Test with Creatinine for UACR, an Urinalysis Complete Test, repeat testing, imaging, or professional evaluation.

Bottom line: Combining creatinine and cystatin C can provide a more accurate estimate of kidney filtration and reduce reliance on either marker alone. Its advantage is improved filtration assessment—not a complete kidney diagnosis.

A Practical Chronic Kidney Disease Testing Approach

Educational framework - not a diagnostic or treatment algorithm. Test selection should reflect risk factors, symptoms, previous results, medication use, and whether the result would change a clinical decision.

1. Start with Both Filtration and Damage

A focused first-line kidney evaluation often includes:

• A Creatinine Test that reports or supports calculated eGFR.
• An Albumin Random Urine Test with Creatinine for UACR.
• An Urinalysis Complete Test to look for blood, protein, cells, casts, glucose, and infection clues.

A Basic Metabolic Panel Test or Comprehensive Metabolic Panel Test - CMP may provide creatinine, glucose, electrolyte, and acid-base context, but neither replaces urine albumin testing.

2. Add Accuracy When Creatinine May Be Misleading

KDIGO recommends starting with serum creatinine and an estimating equation. For adults at risk for CKD, the GFR category should be estimated with the combination of creatinine and cystatin C when cystatin C is available. The combined estimate is especially important when creatinine-based eGFR may be less accurate and the result will affect staging, medication dosing, transplant evaluation, or another clinical decision. The Estimated Glomerular Filtration Rate (eGFR) with Creatinine and Cystatin C provides that laboratory-calculated combined estimate.¹ A cystatin C test with eGFR provides a cystatin C-based estimate for comparison, but neither approach replaces UACR or clinical interpretation.

3. Investigate Cause When the Pattern Is Atypical

Rapid eGFR decline, heavy protein loss, persistent blood in the urine, active urine sediment, resistant hypertension, systemic symptoms, a strong inherited-kidney-disease history, or findings inconsistent with the duration of diabetes may justify additional evaluation. A clinician may use imaging, specialist-directed antibody or infection testing, serum or urine protein studies, genetic assessment, or kidney biopsy. Broad screening with these tests is not appropriate for every mildly abnormal kidney result.

4. Evaluate Complications According to Risk

As filtration declines or symptoms emerge, testing may expand. Selection and frequency should reflect cause, GFR and albuminuria categories, treatment, and prior abnormalities rather than applying the same panel to everyone.

• Complete Blood Count with Differential and Platelets and a Ferritin, Iron and Total Iron Binding Capacity Panel can help evaluate anemia and iron status.
• A Potassium Test can help identify an electrolyte disturbance relevant to CKD and medication monitoring.
• A Carbon Dioxide Test can provide bicarbonate-related acid-base information.
• A Phosphate (as Phosphorus) Test, Calcium Test, PTH Intact Test, and Vitamin D 25-Hydroxy Total Immunoassay Test may be selected when assessing CKD-related mineral and bone patterns.
• An Albumin Test may add context about urinary loss, inflammation, liver function, or nutrition but is not specific to CKD.
• An A1c Test and Lipid Panel Test may help assess connected diabetes and cardiovascular risk.

Core Test Guide

Test	What it measures	Why it may be ordered	General pattern meaning	Factors that can alter it	Cannot establish alone
Creatinine Test with eGFR	Blood creatinine used in a filtration estimate	Initial filtration assessment and monitoring	Lower eGFR generally indicates lower estimated filtration	Muscle mass, meat intake, creatine, illness, medications, assay variation	Cause, chronicity, or kidney damage with preserved eGFR
UACR test	Urine albumin relative to urine creatinine	Detect and monitor albuminuria	Persistent A2 or A3 indicates increasing albumin leakage and risk	Exercise, infection, bleeding, fever, hydration, sample timing	Filtration level, cause, or chronicity from one result
Urinalysis Complete Test	Physical, chemical, and microscopic urine findings	Look for blood, protein, cells, casts, glucose, and infection clues	Abnormal sediment can redirect evaluation toward another cause	Contamination, menstruation, exercise, specimen delay, infection	Quantitative albumin loss or a specific diagnosis
Cystatin C Test with eGFR	Another endogenous filtration marker and eGFR estimate	Improve accuracy when creatinine is less reliable or a decision depends on GFR	Agreement or discordance with creatinine-based eGFR provides context	Inflammation, thyroid status, corticosteroids, smoking, body composition, illness	Cause or exact measured GFR
Estimated Glomerular Filtration Rate (eGFR) with Creatinine and Cystatin C	Both endogenous filtration markers in one eGFR approach	Improve average accuracy and reduce reliance on either marker alone	Most useful when greater precision could change a clinical decision	Non-GFR influences on either marker, acute illness, equation and assay limitations	Albuminuria, cause, chronicity, or exact measured GFR

Complication and Risk Test Guide

Test	Question answered	Typical use	Important limitation	Use status
Renal Function Panel Test	Are filtration, electrolytes, minerals, or acid-base markers abnormal together?	Broader kidney-function context or monitoring	Does not replace quantitative urine albumin	Risk-based or targeted
Complete Blood Count with Differential and Platelets	Is anemia or another blood-cell abnormality present?	Symptoms, lower eGFR, or known CKD	Anemia may reflect iron deficiency, bleeding, inflammation, nutrient deficiency, or marrow disease	Risk-based or targeted
Ferritin, Iron and Total Iron Binding Capacity Panel	Are iron storage and transport patterns contributing to anemia?	Low hemoglobin, fatigue, or treatment planning	Ferritin can rise with inflammation and must be read with the wider pattern	Risk-based or targeted
Potassium Test	Is potassium too high or too low?	Lower filtration, relevant medications, or symptoms	Collection problems can falsely elevate the result; critical results need prompt clinical assessment	Monitoring
Carbon Dioxide Test	Is there a bicarbonate-related acid-base abnormality?	Lower eGFR, weakness, breathing changes, or treatment monitoring	Must be interpreted with other electrolytes and the clinical situation	Risk-based or targeted
Phosphate (as Phosphorus) Test, Calcium Test, PTH Intact Test, and 25-hydroxyvitamin D test	Is a mineral and bone-regulation pattern developing?	Selected according to CKD severity, symptoms, treatment, and prior findings	No single value should trigger an unsupervised dietary or supplement change	Risk-based or targeted

What Kidney Laboratory Testing Can and Cannot Reveal

Testing may help reveal	Testing cannot establish by itself
Whether estimated filtration is reduced	Whether a one-time change is chronic, acute, or temporary
Whether albumin, blood, cells, or casts are present in urine	The exact cause of kidney injury in every case
Whether filtration and albumin leakage are stable or changing over time	Kidney structure, obstruction, cysts, or tumors without imaging
Whether anemia, electrolyte, acid-base, or mineral patterns may be present	Whether symptoms are caused by CKD rather than another condition
Whether a medication or treatment change is associated with a laboratory trend	Whether a medication should be started, stopped, or changed without clinical review
Whether the pattern may justify more focused testing or referral	Findings that require examination, ultrasound, other imaging, genetic counseling, or biopsy

Individual Kidney Tests Versus a Panel

Option	When it may be useful	Advantages	Limitations	Question to ask
Individual Creatinine Test plus individual UACR test	Focused detection or monitoring of the two core kidney axes	Targets filtration and damage directly	May not include urinalysis or complication markers	Do I already have recent related results that make a larger panel duplicative?
Kidney Profile	Convenient paired evaluation when both creatinine-derived eGFR and urine albumin are needed	Combines the central blood and urine measurements	Exact components and preparation instructions must be checked at the time of ordering	Does the current panel include every test needed for my question?
Renal Function Panel Test	Broader filtration, electrolyte, mineral, and acid-base context	Efficient when several related blood markers are clinically relevant	Does not substitute for quantitative urine albumin	Should I add UACR and urinalysis?
Larger kidney or wellness panel	When several risk factors or known complications justify broader evaluation	May reduce separate orders	Greater chance of duplicative or incidental findings; more is not automatically better	Which result would change follow-up, and which tests are unnecessary?

How to Prepare for Kidney Testing and When to Repeat It

Preparation depends on the specific tests ordered. Review the current instructions for each product and tell the healthcare professional interpreting the results about medications, supplements, recent illness, and unusual exercise. Do not stop a prescribed medicine or supplement solely to prepare for testing unless the prescribing professional directs you to do so.

Preparing for the Blood Sample

• Ask whether fasting is required for the complete order. The kidney tests alone may not require fasting, but glucose or lipid testing may change the instructions.
• Avoid intentionally dehydrating or overhydrating before collection. Aim for usual fluid intake unless a clinician has given different instructions.
• Report recent vomiting, diarrhea, fever, infection, heavy exercise, or major dietary changes.
• Report creatine supplements, high-dose supplements, and medications that may change creatinine, potassium, or kidney blood flow.
• For the most comparable trends, use similar collection conditions and, when practical, the same laboratory method.

Preparing for the Urine Sample

For a spot urine albumin-to-creatinine ratio test, a first-morning midstream sample is preferred for confirmation because it generally has less within-person variability. A random sample is acceptable for initial testing when a first-morning sample is not available.¹

Factor	Possible effect	Practical guidance	Important caution
Strenuous exercise	Can temporarily increase urine albumin	Avoid intense exercise for about 24 hours when feasible and appropriate	Do not delay evaluation of concerning symptoms
Urinary infection or fever	Can raise albumin or produce other abnormal urine findings	Document symptoms and obtain clinical guidance about timing	Infection symptoms may require prompt assessment rather than routine retesting
Menstrual or urinary bleeding	Can affect albumin, protein, and blood measurements	Document the circumstance and follow collection guidance	Visible blood in urine outside menstruation requires medical evaluation
Dehydration or very dilute urine	Changes concentration; the ratio corrects for some, but not all, variation	Use usual hydration and note unusual fluid loss or intake	Severe dehydration can cause acute kidney injury
Acute illness or unstable blood pressure or glucose	Can cause a temporary change in albumin excretion	Interpret with the clinical timeline and consider confirmation after stabilization	Urgent abnormalities should not wait three months for follow-up

Why One Abnormal Result Is Usually Not Enough

KDIGO advises repeating an incidentally elevated ACR, hematuria, or low eGFR to confirm CKD. The usual three-month definition is about chronicity, not a rule to ignore urgent findings. A rapidly rising creatinine, a marked fall in eGFR, severe electrolyte disturbance, or concerning urine sediment needs timely medical assessment.¹

How to Understand eGFR, UACR, and Kidney Trends

Interpretation should separate four ideas. The broader guide to reading and understanding lab results explains reference intervals, thresholds, flags, units, and trends in more detail.

Term	What it means	Why it may differ	Patient caution
Laboratory reference interval	The range used by a laboratory to flag results	Method, population, specimen, and laboratory practices	A result inside the interval does not rule out CKD
CKD decision threshold	A guideline value used with persistence and context, such as eGFR below 60 or UACR at or above 30 mg/g	Clinical purpose, chronicity, age, and other kidney markers	A threshold is not an automatic diagnosis from one sample
Monitoring target	An individualized goal used during care	Cause, risk, medications, comorbidities, and tolerance	Do not substitute a generic online target for a personal care plan
Trend	Change across comparable measurements over time	Biological, analytical, and preanalytical variation	Small fluctuations may not mean disease progression

Meaningful Changes Require Context

For people with CKD, KDIGO states that an eGFR change greater than 20% on a subsequent test exceeds expected variability and warrants evaluation. After starting a treatment that changes kidney hemodynamics, a fall greater than 30% also warrants evaluation. For albuminuria monitoring, a doubling of UACR exceeds expected laboratory variability. These are signals for assessment, not instructions to change medication without professional guidance.¹

A Fictional Pattern Walkthrough

Educational example - not a diagnosis. The examples below use qualitative patterns rather than a universal reference range.

Fictional pattern	What it may add	What remains unknown	Possible follow-up question
Stable G2 eGFR with repeatedly A3 UACR	Suggests substantial albumin leakage despite preserved filtration	Cause and whether urine sediment or imaging is abnormal	Does the pattern fit diabetes or hypertension, or is another cause possible?
Muscular adult with eGFRcr 58, eGFRcys 74, combined eGFRcr-cys 66 mL/min/1.73 m2, and UACR below 30 mg/g	The laboratory-calculated combined estimate may reduce reliance on creatinine alone and place filtration in a different GFR category	Whether the pattern persists, whether other kidney-damage markers are present, and which non-GFR factors affect either marker	Would the combined estimate change CKD classification, medication dosing, or the need for measured GFR?
New G3a eGFR with A1 UACR after dehydration	Shows reduced estimated filtration without elevated albumin	Whether the change is temporary, chronic, medication-related, or structural	What happens after hydration and repeat testing under stable conditions?
G3b eGFR with rising UACR and blood on urinalysis	Raises concern for a changing or atypical kidney pattern	Cause, urgency, and whether active urine sediment is present	Is prompt nephrology review, imaging, or specialist testing needed?

The values above are fictional. The combined eGFRcr-cys is calculated with a validated equation; it should not be created by manually averaging the creatinine-based and cystatin C-based eGFR values.⁷

How Often Should eGFR and Urine Albumin Be Monitored?

There is no single schedule for everyone. KDIGO recommends assessing GFR and albuminuria at least annually in people with CKD and more often when progression risk is higher or the result will affect a clinical decision.¹ Diabetes guidance recommends annual eGFR and spot UACR screening for everyone with type 2 diabetes and for people with type 1 diabetes of at least five years' duration.⁴

Monitoring frequency may increase after a meaningful change in kidney results, a relevant medication change, an acute illness, or development of a complication. It may decrease when risk is low and results are stable. A clinician should determine the schedule based on the CGA pattern, cause, comorbidities, and treatment plan.

Risk-Based Referral Is More Informative Than eGFR Alone

For people with CKD G3-G5, KDIGO recommends using an externally validated kidney-failure risk equation. A five-year kidney-failure risk around 3%-5% may support nephrology referral alongside eGFR, UACR, urine findings, and other clinical considerations. Referral may also be appropriate for uncertain cause, rapid progression, persistent hematuria, very high albuminuria, resistant hypertension, persistent electrolyte or acid-base abnormalities, or CKD-related anemia or bone disease.¹

When More Testing Is Not Automatically Better

• Do not use serum creatinine alone as a complete kidney assessment.
• Do not substitute a routine urine dipstick for quantitative UACR when lower levels of albumin matter.
• Do not order broad autoimmune, infection, genetic, or monoclonal-protein testing without a clinical or urine pattern that supports it.
• Do not repeat a clearly unstable or dangerous result on a routine schedule when urgent clinical assessment is needed.
• Do not assume every flagged eGFR in an older adult is harmless, or that every isolated low result proves CKD.
• Do not severely restrict protein, potassium, or phosphorus based on one result. CKD nutrition should be individualized to laboratory findings, medications, nutritional status, and disease severity.
• Do not stop or change a prescription medication solely because eGFR or potassium is flagged. Contact the prescribing professional for interpretation and safety guidance.

Over-testing can create false-positive findings, anxiety, unnecessary repeat testing, avoidable costs, and referrals that do not improve care. A useful test is one that answers a defined question and has a reasonable follow-up plan.

When Prompt or Emergency Evaluation Is Needed

Routine direct-access testing is not a substitute for urgent care. Seek prompt medical assessment for:

• A sudden substantial rise in creatinine or fall in eGFR
• Markedly reduced urine output or inability to urinate
• New visible blood or dark urine
• Rapidly increasing swelling
• Severe vomiting or diarrhea with dehydration
• Shortness of breath, chest symptoms, or inability to lie flat
• Confusion, fainting, severe weakness, or a seizure
• Severe flank pain with fever
• A critically abnormal Potassium Test result or marked weakness, palpitations, or an abnormal heartbeat
• A new kidney abnormality, hypertension, or proteinuria during pregnancy

These findings may reflect acute kidney injury, obstruction, infection, glomerular disease, dangerous electrolyte imbalance, or severe fluid retention.

How Ulta Lab Tests May Help

Eligible customers can review available kidney-related tests online, see current pricing before ordering, complete the required ordering process, visit an available collection location, and access results through an online account. The results can support a more informed conversation with a qualified healthcare professional. Review how direct-access laboratory testing works and what to expect, including ordering, preparation, collection, results, and responsible follow-up.

Direct-access testing is most useful when the test matches a clear question, preparation instructions are followed, and abnormal or changing results receive appropriate follow-up. It does not replace professional assessment of acute symptoms, medication safety, imaging, or a suspected complex kidney disorder.

Related Kidney Tests and Panels

Common Starting Tests

• Creatinine Test - supplies the filtration marker commonly used to calculate eGFR.
• Albumin Random Urine Test with Creatinine - reports the UACR used to assess albuminuria.
• Urinalysis Complete Test - looks for blood, protein, glucose, cells, casts, and infection clues.
• Basic Metabolic Panel Test or Comprehensive Metabolic Panel Test - CMP - adds glucose, electrolyte, and acid-base context.

Targeted or Confirmatory Tests

• Estimated Glomerular Filtration Rate (eGFR) with Creatinine and Cystatin C - uses both filtration markers for a generally more accurate combined eGFR when precision matters.
• Cystatin C Test with eGFR - may add accuracy when creatinine is less reliable and the GFR estimate affects a decision.
• Renal Function Panel Test - provides a broader kidney, electrolyte, mineral, and acid-base blood profile.
• Kidney Profile - combines central blood and urine kidney measures in one product; confirm current components before ordering.

Complication and Risk Tests

• Complete Blood Count with Differential and Platelets and ferritin and iron studies for anemia context.
• Potassium Test and Carbon Dioxide Test for selected electrolyte and acid-base monitoring.
• Phosphate (as Phosphorus) Test, Calcium Test, PTH Intact Test, and Vitamin D 25-Hydroxy Total Immunoassay Test for risk-based mineral and bone assessment.
• A1c Test and Lipid Panel Test for connected diabetes and cardiovascular risk.
• Albumin Test for context about blood albumin, recognizing that low values can have kidney, liver, inflammatory, nutritional, or digestive causes.

Questions to Ask a Healthcare Professional

1. Do my eGFR and UACR results tell the same story or different stories?
2. Is this result likely to be acute, temporary, or chronic?
3. What previous results can establish a trend or chronicity?
4. Should an elevated random UACR be repeated with a first-morning sample?
5. Could muscle mass, exercise, diet, supplements, illness, or medication affect my creatinine-derived eGFR?
6. Would cystatin C or a combined creatinine-cystatin C estimate change a clinical decision?
7. Does my urinalysis suggest blood, infection, or an active urine-sediment pattern?
8. What is my complete cause-GFR-albuminuria classification?
9. Do I need testing for anemia, potassium, acid-base, or mineral and bone complications?
10. How often should eGFR and UACR be repeated for my risk level?
11. Would a kidney-failure risk equation or nephrology referral add useful information?
12. Do any symptoms or results require urgent evaluation rather than routine follow-up?

Frequently Asked Questions

Can you have chronic kidney disease with a normal eGFR?

Yes. Persistent albuminuria, blood or abnormal sediment in the urine, structural kidney abnormalities, or certain inherited disorders can establish CKD even when eGFR is 60 or higher. That is why a urine albumin-to-creatinine ratio test and other kidney-damage markers should be considered alongside eGFR.

Can urine albumin be normal when eGFR is low?

Yes. A reduced eGFR may occur with little albuminuria. Possible explanations include vascular disease, prior kidney injury, medication effects, age-related change, or a kidney disorder that does not produce substantial albumin leakage. Persistent results, the urinalysis, medical history, and sometimes imaging help clarify the pattern.

Does one low eGFR or high UACR result mean I have CKD?

Not automatically. CKD generally requires an abnormality that persists for at least three months or other evidence of chronic kidney damage. Dehydration, illness, infection, exercise, bleeding, medication effects, and acute kidney injury can alter results. Unexpected abnormalities should be repeated or evaluated on a timetable appropriate to their severity.

What is the difference between creatinine and eGFR?

Creatinine is a measured waste product in blood. eGFR is a calculated estimate of kidney filtration that uses the creatinine result and personal variables in a validated equation. A Creatinine Test may therefore report both the measured creatinine and an estimated GFR. Muscle mass and other non-kidney factors can influence the estimate.

Is microalbumin the same as UACR?

The older term microalbumin commonly refers to detecting moderately increased urine albumin, not a smaller type of albumin. UACR is the preferred quantitative ratio: it compares urine albumin with urine creatinine to reduce the effect of urine concentration. The Albumin Random Urine Test with Creatinine provides this relationship.

When can cystatin C add useful information?

A Cystatin C Test with eGFR may help when creatinine is likely to be less accurate because of unusual muscle mass, amputation, frailty, extreme exercise, diet, supplements, or illness. When greater accuracy is needed, the Estimated Glomerular Filtration Rate (eGFR) with Creatinine and Cystatin C generally provides a more accurate combined estimate than either marker alone, especially when staging, medication dosing, or another decision could change.

What if my creatinine-based and cystatin C-based eGFR results are different?

The estimates can differ because creatinine and cystatin C are affected by different non-kidney factors. Muscle mass, diet, supplements, medications, corticosteroid use, thyroid dysfunction, inflammation, smoking, adiposity, and acute illness may influence one marker more than the other. Do not manually average the two results. The laboratory-calculated Estimated Glomerular Filtration Rate (eGFR) with Creatinine and Cystatin C is generally more accurate when the two estimates disagree, although a healthcare professional may favor the less-affected marker or measured GFR when one marker has a strong known distortion.¹⁸

Do I need to fast for eGFR and urine albumin testing?

Fasting is not always required for the kidney measurements alone. It may be required when the order includes glucose, lipids, or another test with fasting instructions. Follow the current instructions for the complete order. Use usual hydration, disclose recent illness and supplements, and avoid intense exercise before urine albumin testing when feasible.

Why is a first-morning urine sample preferred?

A first-morning midstream sample generally has less within-person variability and correlates well with daily albumin excretion. KDIGO recommends confirming a random UACR at or above 30 mg/g with a subsequent first-morning sample. A random sample can still be used for initial testing when a first-morning sample is unavailable.

How often should eGFR and UACR be checked?

People with CKD generally need both assessed at least annually, with more frequent monitoring when progression risk is higher or results affect treatment decisions. Diabetes guidance recommends annual screening for everyone with type 2 diabetes and for people with type 1 diabetes of at least five years' duration. Individual schedules depend on risk and treatment.

When should a nephrologist be involved?

Referral may be appropriate for uncertain cause, rapid progression, very high albuminuria, persistent blood or casts in urine, resistant hypertension, persistent electrolyte or acid-base problems, CKD-related anemia or bone disease, or elevated predicted kidney-failure risk. The decision should combine eGFR, UACR, urine findings, symptoms, cause, and local referral practices.

Conclusion: Read Filtration, Damage, and Time Together

Chronic kidney disease testing is strongest when eGFR and urine albumin are interpreted as complementary measurements. A creatinine-derived eGFR offers a practical first estimate of filtration; a combined creatinine-cystatin C eGFR may improve accuracy when the decision requires it. UACR helps reveal albumin leakage and kidney damage. Urinalysis, complication testing, clinical history, and trends add context when the pattern requires it.

The central principle is simple: do not judge kidney health from creatinine alone, and do not interpret one elevated urine albumin result without confirmation and context. Use both kidney axes, determine whether abnormalities persist, classify cause-GFR-albuminuria risk, and review significant findings with a qualified healthcare professional. Explore kidney disease testing options and choose only the tests that answer a defined question.

Primary References

1. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Disease: Improving Global Outcomes; published March 2024. Supports CKD definition and CGA classification; paired GFR and albumin testing; confirmation; cystatin C use; monitoring changes; and risk-based referral.
2. Chronic Kidney Disease Tests and Diagnosis. National Institute of Diabetes and Digestive and Kidney Diseases. Supports the complementary roles of GFR and urine albumin and the value of trends.
3. Identify and Evaluate Patients with Chronic Kidney Disease. National Institute of Diabetes and Digestive and Kidney Diseases. Supports risk-based testing and paired eGFR and spot UACR assessment.
4. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes - 2026. American Diabetes Association Professional Practice Committee; 2026. See also the ADA's 2026 CKD screening infographic. Supports annual spot UACR and eGFR screening in diabetes.
5. Estimated Glomerular Filtration Rate (eGFR). National Kidney Foundation; updated February 5, 2026. Supports patient-facing explanations of eGFR, creatinine limitations, and GFR estimation.
6. Urine Albumin-Creatinine Ratio (uACR). National Kidney Foundation; reviewed May 1, 2023. Supports quantitative UACR use, collection considerations, and interpretation of albuminuria.
7. eGFR Equations for Adults. National Institute of Diabetes and Digestive and Kidney Diseases; last reviewed May 2025. Supports the race-free 2021 CKD-EPI equations, the greater average accuracy of combined creatinine-cystatin C eGFR, and its use near critical decision values.
8. Clinical Measurements and eGFR Accuracy. National Institute of Diabetes and Digestive and Kidney Diseases; last reviewed May 2025. Supports non-GFR influences on creatinine and cystatin C and the rationale for combining the two markers.
9. Determining Drug Dosing in Adults with Chronic Kidney Disease. National Institute of Diabetes and Digestive and Kidney Diseases. Supports use of combined creatinine-cystatin C eGFR near drug-dosing cutoffs, body-surface-area considerations, and measured GFR when unusually high dosing accuracy is needed.

Disclosure: Ulta Lab Tests offers laboratory-testing services and may link to tests or panels discussed on this page. This content is educational and does not provide individual diagnosis or treatment